CAI Stock Analysis: Caris Life Sciences, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.035m USD | 12M Return: -34.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.3M
Qual. Beats: 0
Rev. Trend: 97.6%
Warnings
Tailwinds
No distinct edge detected
Seasonality 1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Caris Life Sciences (NASDAQ: CAI) is an AI-driven TechBio company that provides molecular profiling services to hospitals, institutions, and patients in the U.S. and internationally. The company combines whole exome, whole transcriptome, and whole genome sequencing with proprietary AI/machine learning algorithms to support precision oncology applications, including therapy selection, multi-cancer early detection, and minimal residual disease monitoring. Its product portfolio spans tissue- and blood-based assays (MI Profile, Caris Assure, Precision Whole Genome, Caris Detect, Caris WGS MRD, and Caris ChromoSeq), and it also offers laboratory and data-driven research services to biopharmaceutical clients. Founded in 2008 and headquartered in Irving, Texas, Caris completed its IPO in mid-2025 and operates within the Life Sciences Tools & Services sub-industry, a sector that supplies the analytical technologies and genomic data used by pharma, researchers, and clinicians to develop targeted therapies and diagnostics.
- MI Profile and Assure drive core molecular profiling revenue
- Caris Detect multi-cancer early detection scales commercially
- Post-IPO cash burn and capital allocation under investor scrutiny
| Net Income: 34.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 244.5 > 1.0 |
| NWC/Revenue: 95.92% < 20% (prev 2.16%; Δ 93.76% < -1%) |
| CFO/TA 0.13 > 3% & CFO 147.4m > Net Income 34.0m |
| Net Debt (-343.1m) to EBITDA (104.5m): -3.28 < 3 |
| Current Ratio: 7.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (282.6m) vs 12m ago 10.90% < -2% |
| Gross Margin: 68.72% > 18% (prev 43.44%; Δ 25.28% > 0.5%) |
| Asset Turnover: 124.8% > 50% (prev 138.0%; Δ -13.23% > 0%) |
| Interest Coverage Ratio: 1.47 > 6 (EBIT TTM 83.8m / Interest Expense TTM 56.9m) |
| A: 0.75 (Total Current Assets 1.01b - Total Current Liabilities 143.9m) / Total Assets 1.16b |
| B: -2.19 (Retained Earnings -2.55b / Total Assets 1.16b) |
| C: 0.12 (EBIT TTM 83.8m / Avg Total Assets 727.0m) |
| D: 1.04 (Book Value of Equity 593.5m / Total Liabilities 568.9m) |
| Altman-Z'' = -0.37 = B |
| DSRI: 0.50 (Receivables 90.5m/80.2m, Revenue 907.3m/402.5m) |
| GMI: 0.63 (GM 43.44% / 68.72%) |
| AQI: 0.28 (AQ_t 0.06 / AQ_t-1 0.20) |
| SGI: 2.25 (Revenue 907.3m / 402.5m) |
| TATA: -0.10 (NI 34.0m - CFO 147.4m) / TA 1.16b) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 17.47 with a total of 2,647,704 shares traded. Over the past week, the price has changed by -4.64%, over one month by +8.24%, over three months by -6.83% and over the past year by -34.15%.
Current recommended Stop Loss: 15.80 (which is 9.6% or 1.4 ATR below the current price).
Caris Life Sciences, Common has no consensus analysts rating.
P/E Forward = 48.0769
P/S = 5.549
P/B = 8.714
Revenue TTM = 907.3m USD
EBIT TTM = 83.8m USD
EBITDA TTM = 104.5m USD
Long Term Debt = 381.4m USD (from longTermDebt, last quarter)
Short Term Debt = 6.01m USD (from shortTermDebt, last quarter)
Debt = 480.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 49.4m
Net Debt = -343.1m USD (calculated: Debt 480.3m - CCE 823.5m)
Enterprise Value = 4.69b USD (5.03b + Debt 480.3m - CCE 823.5m)
Interest Coverage Ratio = 1.47 (Ebit TTM 83.8m / Interest Expense TTM 56.9m)
EV/FCF = 46.04x (Enterprise Value 4.69b / FCF TTM 101.9m)
FCF Yield = 2.17% (FCF TTM 101.9m / Enterprise Value 4.69b)
FCF Margin = 11.23% (FCF TTM 101.9m / Revenue TTM 907.3m)
Net Margin = 3.75% (Net Income TTM 34.0m / Revenue TTM 907.3m)
Gross Margin = 68.72% ((Revenue TTM 907.3m - Cost of Revenue TTM 283.8m) / Revenue TTM)
Gross Margin QoQ = 65.39% (prev 75.43%)
Tobins Q-Ratio = 4.04 (Enterprise Value 4.69b / Total Assets 1.16b)
Interest Expense / Debt = 11.84% (Interest Expense 56.9m / Debt 480.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 66.2m (EBIT 83.8m * (1 - 21.00%))
Current Ratio = 4.75 (Total Current Assets 1.01b / Total Current Liabilities 213.7m)
Debt / Equity = 0.81 (Debt 480.3m / totalStockholderEquity, last quarter 593.5m)
Debt / EBITDA = -3.28 (Net Debt -343.1m / EBITDA 104.5m)
Debt / FCF = -3.37 (Net Debt -343.1m / FCF TTM 101.9m)
Total Stockholder Equity = 525.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.67% (Net Income 34.0m / Total Assets 1.16b)
RoE = 6.47% (Net Income TTM 34.0m / Total Stockholder Equity 525.5m)
RoCE = 9.25% (EBIT 83.8m / Capital Employed (Equity 525.5m + L.T.Debt 381.4m))
RoIC = 6.76% (NOPAT 66.2m / Invested Capital 979.1m)
WACC = 8.27% (E(5.03b)/V(5.51b) * Re(8.17%) + D(480.3m)/V(5.51b) * Rd(11.84%) * (1-Tc(0.21)))
Discount Rate = 8.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.81 | Cagr: 244.1%
[DCF] Terminal Value 75.44% ; FCFF base≈101.9m ; Y1≈102.3m ; Y5≈108.4m
[DCF] Fair Price = 7.18 (EV 1.69b - Net Debt -343.1m = Equity 2.03b / Shares 282.7m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 97.56 | Revenue CAGR: 62.87% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.01 | Chg30d=N/A | Revisions=-50% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=-24.96% | Revisions=-22% | Analysts=9
EPS current Year (2026-12-31): EPS=0.13 | Chg30d=-5.14% | Revisions=-15% | GrowthEPS=+132.6% | GrowthRev=+23.7%
EPS next Year (2027-12-31): EPS=0.37 | Chg30d=-2.87% | Revisions=+0% | GrowthEPS=+175.3% | GrowthRev=+19.9%
[Analyst] Revisions Ratio: -25% (up=12, down=21)